EliLilly | Pharmaceutical Sector
| DATE/WEEK |
HIGHLIGHTS |
FOR |
EPS |
|
Eli Liily |
No 4 |
... |
|
Q4-2026 |
|
| |
|
|
|
Eli Liily |
No 3 |
... |
|
Q3-2026 |
|
| |
|
|
|
Eli Liily |
No 2 |
... |
|
Q2-2026 |
|
| |
|
|
|
Eli Lilly blows past quarterly estimates, posts strong outlook as Zepbound and Mounjaro sales soar. Eli Lilly posted on Wednesday fourth-quarter earnings and revenue and 2026 guidance that blew past estimates, as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro soars.The guidance comes in stark contrast to the outlook of rival Novo Nordisk, which warned on Tuesday that it sees sales and profit declining as much as 13% this year. Lilly is working to maintain its dominance in the booming market for those drugs, called GLP-1s, as Novo sees an explosive U.S. launch for its new Wegovy pill for obesity. The pharmaceutical giant anticipates its 2026 revenue will come in between $80 billion and $83 billion. Analysts expected revenue of $77.62 billion, according to LSEG.Lilly also projects adjusted earnings to be between $33.50 and $35 per share for the year. That compares with analysts’ estimate of $33.23 per share, according to LSEG. |
No 1 |
$33.50 |
|
Q1-2026 |
|
| |
|
|
 |
|
Eli Lilly reported third-quarter earnings and revenue that topped estimates and hiked its full-year outlook, as the company continued to see strong demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro.Here’s what Eli Lilly reported for the third quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG: Earnings per share: $7.02 adjusted vs. $5.69 expected Revenue: $17.60 billion vs. $16.01 billion expected. |
No 4 |
$1.85 |
|
Q3-2025 |
|
| |
|
|
|
Eli Lilly on Thursday hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its blockbuster weight loss and diabetes drugs. Here’s what Eli Lilly reported for the second quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG: Earnings per share: $6.31 adjusted vs. $5.57 expected. Revenue: $15.56 billion vs. $14.71 billion expected. |
No 3 |
$1.57 |
|
Q2-2025 |
|
| |
|
|
|
Eli Lilly sales soar 45% on weight loss drug demand, but drugmaker cuts profit outlook after cancer treatment deal.Eli Lilly on Thursday reported first-quarter revenue and earnings that topped estimates as demand for its weight loss and diabetes drugs soared, but lowered its full-year profit guidance due to charges related to a recent cancer treatment deal.Here’s what Eli Lilly reported for the first quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG: Earnings per share: $3.34 adjusted vs. $3.02 expected Revenue: $12.73 billion vs. $12.67 billion expected. |
No 2 |
$1.65 |
|
Q1-2025 |
|
| |
|
|
|
Eli Lilly beats on earnings even as weight loss, diabetes drug sales fall short. Eli Lilly on Thursday reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro soared. Here’s what Eli Lilly reported for the fourth quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG: Earnings per share: $5.32 adjusted vs. $4.95 expected. Revenue: $13.53 billion vs. $13.57 billion expected. |
No 1 |
$2.40 |
|
Q4-2024 |
|
| |
|
|
|
|
Eli Lilly beats on quarterly profit, hikes full-year guidance on strong sales of Zepbound, Mounjaro.Eli Lilly on Tuesday reported first-quarter adjusted profit that topped Wall Street’s expectations and hiked its full-year guidance on strong sales of its blockbuster diabetes drug Mounjaro and newly launched weight loss treatment Zepbound.Here’s what Eli Lilly reported for the first quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG: Earnings per share: $2.58 adjusted vs. $2.46 expected Revenue: $8.77 billion vs. $8.92 billion expected
|
No 4 |
$1.64 |
|
Q3-2024 |
|
| |
|
|
|
Eli Lilly blows past estimates, hikes guidance as Zepbound, Mounjaro sales soar.Eli Lilly reported second-quarter earnings and revenue that blew past expectations and hiked its full-year revenue outlook by $3 billion as sales of its blockbuster diabetes drug Mounjaro and weight loss injection Zepbound spike. Here’s what Eli Lilly reported for the second quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG:m Earnings per share: $3.92 adjusted vs. $2.60 expected. Revenue: $11.30 billion vs. $9.92 billion expected |
No 3 |
$1.40 |
|
Q2-2024 |
|
| |
|
|
|
Eli Lilly beats on quarterly profit, hikes full-year guidance on strong sales of Zepbound, Mounjaro.Eli Lilly on Tuesday reported first-quarter adjusted profit that topped Wall Street’s expectations and hiked its full-year guidance on strong sales of its blockbuster diabetes drug Mounjaro and newly launched weight loss treatment Zepbound.Here’s what Eli Lilly reported for the first quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG: Earnings per share: $2.58 adjusted vs. $2.46 expected Revenue: $8.77 billion vs. $8.92 billion expected |
No 2 |
$1.53 |
|
Q1-2024 |
|
| |
|
|
|
Eli Lilly results blow past estimates on strong Zepbound launch, surging Mounjaro revenue. Eli Lilly on Tuesday reported fourth-quarter revenue and adjusted earnings that topped expectations on the strong launch of its new weight loss drug, Zepbound, and higher prices for its blockbuster diabetes treatment, Mounjaro.Here’s what Eli Lilly reported for the fourth quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG, formerly known as Refinitiv: Earnings per share: $2.49 adjusted vs. $2.22 expected Revenue: $9.35 billion vs. $8.93 billion expected |
No 1 |
$2.18 |
|
Q4-2023 |
|
| |
|
|
|
|
Eli Lilly results top estimates on Mounjaro strength but slashes full-year profit outlook. Eli Lilly on Thursday reported third-quarter revenue and adjusted earnings that topped estimates on strong demand for its diabetes drug Mounjaro, but slashed its full-year profit guidance due to charges primarily related to its recent acquisitions.Here’s what Eli Lilly reported for the third quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG, formerly known as Refinitiv: Earnings per share: 10 cents per share adjusted vs. 13 cents loss per share expected. Revenue: $9.50 billion vs. $8.95 billion expected. |
No 4 |
$1.46 |
|
Q3-2023 |
|
| |
|
|
|
Eli Lilly raises full-year guidance as Mounjaro, other drugs drive second-quarter profit up 85%.Eli Lilly on Tuesday raised its full-year guidance as second-quarter profit jumped 85% from the same period a year ago on strong sales from the pharmaceutical giant’s diabetes treatment Mounjaro and other drugs.Here’s how Eli Lilly performed, compared with Wall Street expectations, based on a survey of analysts by Refinitiv: Adjusted earnings: $2.11 per share, vs. $1.98 per share expected Revenue: $8.31 billion, vs. $7.58 billion expected |
No 3 |
$1.26 |
|
Q2-2023 |
|
| |
|
|
|
Eli Lilly misses on earnings but raises full-year guidance.Eli Lilly’s first-quarter earnings missed expectations Thursday, but the pharmaceutical company raised its full-year guidance.Here’s how the company performed compared with analysts’ estimates compiled by Refinitiv: Adjusted earnings: $1.62 per share, vs $1.73 per share expected. Revenue: $6.96 billion, vs. $6.86 billion expected.Eli Lilly fell short of quarterly earnings expectations but raised its full-year guidance. |
No 2 |
$1.52 |
|
Q1-2023 |
|
| |
|
|
|
Lilly Reports Fourth-Quarter 2022 Financial Results, Core Business Growth and Pipeline Advancements Support Strong Long-Term Outlook.Revenue in Q4 2022 decreased 9%. Excluding COVID-19 antibodies, revenue in Q4 2022 increased 5%, or 10% on a constant currency basis, driven by volume growth of key growth products, partially offset by lower Alimta revenue. Excluding COVID-19 antibodies, total worldwide volume in Q4 2022 increased 13%.EPS – Reported 2.14 2021 1.90 Change 13 % |
No 1 |
$1.88 |
|
Q4-2022 |
|
| |
|
|
|
|
Lilly Reports Solid Third-Quarter 2022 Financial Results and Continued Pipeline Progress. Lilly's revenue in Q3 2022 increased 2%, or 7% on a constant currency basis, primarily driven by volume growth of key growth products, partially offset by lower realized prices and lower Alimta revenue following the entry of generics. Total worldwide volume in Q3 2022 increased 14%.Q3 2022 EPS increased 32% to $1.61 on a reported basis and increased 12% to $1.98 on a non-GAAP basis. Q3 2022 reported and non-GAAP EPS are both inclusive of $0.06 of acquired IPR&D and development milestone charges. |
No 4 |
$1.29 |
|
Q3-2022 |
|
| |
|
|
|
Lilly Reports Second-Quarter Financial Results, Highlights Momentum of New Medicines and Pipeline Advancements. Lilly's revenue in Q2 2022 decreased 4%. On a constant currency basis, revenue decreased 1% as lower realized prices and lower Alimta revenue following the entry of generics more than offset volume growth from key growth products. Total revenue grew 6% excluding revenue from Alimta, the sale of the company's rights to Cialis in China in Q2 2021, and COVID-19 antibodies. Q2 2022 EPS decreased 31% to $1.05 on a reported basis and decreased 32% to $1.25 on a non-GAAP basis. Q2 2022 reported and non-GAAP EPS are both inclusive of $0.46 of acquired IPR&D and development milestone charges. |
No 3 |
$1.20 |
|
Q2-2022 |
|
| |
|
|
|
Eli Lilly and Company LLY reported first-quarter 2022 adjusted earnings per share of $2.62, which beat the Consensus Estimate of $2.32. Earnings rose 63% year over year, driven by higher operating profits.Revenues of $7.81 billion also beat the Zacks Consensus Estimate of $7.52 billion. Sales increased 15% year over year. In the reported quarter, Lilly recorded $1.47 billion of revenues from COVID-19 therapies. |
No 2 |
$1.52 |
|
Q1-2022 |
|
| |
|
|
|
Lilly Reports Solid Fourth-Quarter and Full-Year 2021 Financial Results, Recent Late-Stage Pipeline Successes Set Up Next Wave of Innovative Medicines for Patients.Revenue in the fourth quarter of 2021 increased 8 percent, driven by volume growth of 11 percent. Excluding COVID-19 antibodies, fourth-quarter 2021 revenue grew 6 percent.Fourth-quarter 2021 earnings per share (EPS) decreased 18 percent to $1.90 on a reported basis and increased 8 percent to $2.49 on a non-GAAP basis. Full-year 2021 EPS decreased 10 percent to $6.12 on a reported basis and increased 20 percent to $8.16 on a non-GAAP basis. |
No 1 |
$2.10 |
|
Q4-2021 |
|
| |
|
|
|
|
2021 Financial Results as Pipeline Success Strengthens Future Growth Potential. Revenue in the third quarter of 2021 increased 18 percent, driven by volume growth of 17 percent. When excluding revenue from COVID-19 therapies, revenue growth was 11 percent in both third-quarter and year-to-date 2021.Third-quarter 2021 earnings per share (EPS) decreased to $1.22 on a reported basis and increased to $1.94 on a non-GAAP basis, representing 38 percent growth versus prior year.ey growth products, consisting of Trulicity, Taltz, Verzenio, Jardiance, Emgality, Olumiant, Tyvyt, Retevmo and Cyramza, contributed 17 percentage points of revenue growth and represented approximately 58 percent of total revenue in the third quarter of 2021, excluding revenue from COVID-19 therapies. Revenue from Trulicity, Taltz, Verzenio and Emgality each grew by more than 30 percent versus prior year. |
No 4 |
$1.24 |
|
Q3-2021 |
|
| |
|
|
|
Drugmaker Eli Lilly profit hit by weak demand for pandemic drugs.Drugmaker Eli Lilly, fell short of quarterly profit expectations on Tuesday, as persistent regulatory actions in the United States and lower demand hurt sales of its Covid-19 therapies.Excluding items, Lilly earned $1.87 per share, missing estimates of $1.89 per share, according to Refinitiv IBES data. Net income fell to $1.39 billion in the quarter ended June 30 from $1.41 billion a year ago. |
No 3 |
$1.30 |
|
Q2-2021 |
|
| |
|
|
|
Eli Lilly profit forecast trimmed as vaccines dent U.S. demand for Covid drugs. Eli Lilly on Tuesday missed expectations for first-quarter profit and cut the top end of its full-year earnings forecast as demand waned for its Covid-19 antibody therapies with the U.S. vaccine rollout in full swing.Lilly reported sales of $810.1 million from its COVID-19 drugs in the quarter, below estimates of $985 million and fourth-quarter sales of $871.2 million. The company now expects adjusted full-year earnings of $7.80 to $8.00 per share, from its prior forecast of $7.75 to $8.40 per share.Excluding items, the company earned $1.87 per share, missing analysts’ estimates by 26 cents, according to IBES data from Refinitiv. |
No 2 |
$1.40 |
|
Q1-2021 |
|
| |
|
|
|
Eli Lilly profit beats estimates on demand for its cancer and diabetes drugs.Eli Lilly
beat Wall Street estimates for fourth-quarter profit on Friday, boosted by strong demand for its diabetes and cancer drugs and a partial lift from sales of its Covid-19 antibody treatment.The company recorded $871.2 million in quarterly sales of the Covid-19 therapy, bamlanivimab, benefiting from the U.S. government’s move to stock up on the drug for emergency use. Mizuho analysts had expected the drug to bring in sales of $813 million.Sales of diabetes drug Trulicity rose 24% to $1.50 billion, beating estimates of $1.39 billion, according to seven analysts polled by Refinitiv. |
No 1 |
$1.68 |
|
Q4-2020 |
|
| |
|
|
 |
|
|
|
